

TABLE 160: GENOTYPE 1 TREATMENT-NAIVE WITH CIRRHOSIS — EMERGING TREATMENTS: RELATIVE RISKS AND RISK DIFFERENCE FOR ALL TREATMENT COMPARISONS — RANDOM EFFECTS MODEL

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SIM12 + SOF12	PR48	2.25 (0.94 to 2.90)	50.46 (−2.42 to 63.43)
T12 PR24-48 RGT q8		1.44 (0.64 to 2.21)	17.19 (−13.98 to 43.46)
T12 PR24-48 RGT q12		1.54 (0.58 to 2.37)	21.12 (−16.20 to 49.42)
SOF12 + PR12		2.10 (1.14 to 2.74)	43.64 (5.26 to 58.96)
SIM12 PR24-48 RGT		1.68 (1.06 to 2.36)	26.51 (2.29 to 47.30)
B24 PR28-48 RGT		0.64 (0.17 to 1.65)	−13.83 (−34.32 to 24.54)
SOF12 + SIM12 + RBV12		2.29 (0.66 to 2.95)	51.78 (−13.39 to 64.62)
SOF24 + RBV24		1.76 (0.61 to 2.58)	29.83 (−15.32 to 55.42)
DCV24 + ASU24		2.28 (1.70 to 2.87)	50.05 (29.80 to 61.72)
SOF12 + LDV12		2.45 (1.97 to 3.02)	56.65 (42.78 to 65.23)
SOF12 + LDV12 + RBV12		2.45 (1.98 to 3.02)	56.74 (42.17 to 65.56)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SOF24 + LDV24 + RBV24		2.46 (2.00 to 3.04)	57.23 (43.48 to 65.75)
GRZ12 + ELB12		2.49 (2.05 to 3.05)	58.03 (47.33 to 65.88)
DCV12 + ASU12 + BEC12 + RBV12		2.51 (2.07 to 3.08)	58.75 (48.75 to 66.55)
DCV12 + ASU12 + BEC12		1.00 (0.00 to 2.79)	-0.08 (-41.63 to 62.94)
GRZ12 + ELB12 (50 mg q.d.)		2.43 (1.91 to 3.01)	56.23 (38.73 to 65.20)
GRZ18 + ELB18 (50 mg q.d.)		2.36 (1.79 to 2.94)	53.45 (32.93 to 63.68)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		2.28 (1.63 to 2.87)	50.32 (25.34 to 61.67)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		2.44 (1.94 to 3.02)	56.60 (39.41 to 65.47)
T12 PR24-48 RGT q8	SIM12 + SOF12	0.66 (0.33 to 1.34)	-29.85 (-59.80 to 14.56)
T12 PR24-48 RGT q12		0.71 (0.29 to 1.51)	-25.82 (-62.43 to 20.82)
SOF12 + PR12		0.94 (0.60 to 1.87)	-5.69 (-33.03 to 35.75)
SIM12 PR24-48 RGT		0.75 (0.47 to 1.93)	-22.41 (-50.08 to 33.79)
B24 PR28-48 RGT		0.30 (0.08 to 1.01)	-60.19 (-87.82 to 0.26)
SOF12 + SIM12 + RBV12		1.01 (0.41 to 1.82)	0.97 (-48.26 to 37.31)
SOF24 + RBV24		0.80 (0.30 to 1.78)	-17.45 (-61.56 to 32.02)
DCV24 + ASU24		0.99 (0.76 to 2.53)	-0.73 (-22.38 to 54.06)
SOF12 + LDV12		1.06 (0.90 to 2.64)	5.39 (-9.34 to 58.09)
SOF12 + LDV12 + RBV12		1.06 (0.88 to 2.68)	5.66 (-11.30 to 59.63)
SOF24 + LDV24 + RBV24		1.07 (0.90 to 2.65)	6.13 (-9.47 to 59.04)
GRZ12 + ELB12		1.07 (0.95 to 2.68)	6.72 (-5.16 to 60.33)
DCV12 + ASU12 + BEC12 + RBV12		1.08 (0.96 to 2.74)	7.48 (-3.74 to 61.82)
DCV12 + ASU12 + BEC12		0.47 (0.00 to 1.80)	-42.01 (-96.11 to 38.65)
GRZ12 + ELB12 (50 mg q.d.)		1.05 (0.86 to 2.63)	4.69 (-12.97 to 58.57)
GRZ18 + ELB18 (50 mg q.d.)		1.03 (0.80 to 2.54)	2.48 (-18.43 to 55.73)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		1.00 (0.74 to 2.42)	-0.28 (-24.47 to 51.85)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		1.06 (0.87 to 2.64)	5.53 (-12.00 to 58.60)
T12 PR24-48 RGT q12	T12 PR24-48 RGT q8	1.06 (0.63 to 1.61)	3.49 (-19.08 to 24.39)
SOF12 + PR12		1.43 (1.05 to 2.44)	24.03 (3.40 to 44.97)
SIM12 PR24-48 RGT		1.16 (0.65 to 2.79)	9.01 (-25.50 to 47.62)
B24 PR28-48 RGT		0.46 (0.11 to 1.58)	-29.36 (-65.11 to 18.91)
SOF12 + SIM12 + RBV12		1.53 (0.50 to 3.18)	30.89 (-28.16 to 63.45)
SOF24 + RBV24		1.19 (0.59 to 2.06)	11.18 (-21.22 to 38.06)
DCV24 + ASU24		1.56 (1.03 to 3.64)	31.42 (2.14 to 66.24)
SOF12 + LDV12		1.69 (1.15 to 3.84)	39.01 (11.93 to 70.55)
SOF12 + LDV12 + RBV12		1.69 (1.15 to 3.85)	38.84 (11.45 to 70.72)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SOF24 + LDV24 + RBV24		1.70 (1.16 to 3.87)	39.36 (12.53 to 71.18)
GRZ12 + ELB12		1.72 (1.17 to 3.92)	40.40 (13.97 to 72.29)
DCV12 + ASU12 + BEC12 + RBV12		1.73 (1.18 to 3.96)	41.32 (14.83 to 73.11)
DCV12 + ASU12 + BEC12		0.72 (0.00 to 2.85)	-14.60 (-72.15 to 60.08)
GRZ12 + ELB12 (50 mg q.d.)		1.67 (1.13 to 3.80)	37.90 (10.31 to 70.37)
GRZ18 + ELB18 (50 mg q.d.)		1.63 (1.07 to 3.72)	35.27 (5.12 to 68.25)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		1.56 (1.00 to 3.54)	31.85 (0.04 to 64.89)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		1.69 (1.14 to 3.82)	38.62 (10.76 to 70.38)
SOF12 + PR12	T12 PR24-48 RGT q12	1.34 (0.90 to 2.89)	20.33 (-6.55 to 50.19)
SIM12 PR24-48 RGT		1.09 (0.60 to 3.04)	5.43 (-31.62 to 48.98)
B24 PR28-48 RGT		0.44 (0.10 to 1.62)	-32.36 (-70.61 to 18.39)
SOF12 + SIM12 + RBV12		1.42 (0.47 to 3.64)	26.30 (-32.50 to 66.34)
SOF24 + RBV24		1.12 (0.69 to 1.80)	7.55 (-15.86 to 29.42)
DCV24 + ASU24		1.46 (0.96 to 4.01)	27.69 (-3.04 to 68.08)
SOF12 + LDV12		1.59 (1.07 to 4.23)	35.28 (6.18 to 72.56)
SOF12 + LDV12 + RBV12		1.58 (1.06 to 4.25)	35.06 (5.41 to 72.86)
SOF24 + LDV24 + RBV24		1.59 (1.08 to 4.26)	35.60 (7.10 to 73.39)
GRZ12 + ELB12		1.60 (1.10 to 4.36)	36.33 (8.54 to 74.52)
DCV12 + ASU12 + BEC12 + RBV12		1.62 (1.11 to 4.36)	37.32 (9.69 to 74.95)
DCV12 + ASU12 + BEC12		0.68 (0.00 to 2.98)	-17.24 (-77.73 to 60.95)
GRZ12 + ELB12 (50 mg q.d.)		1.56 (1.06 to 4.23)	34.02 (5.15 to 72.31)
GRZ18 + ELB18 (50 mg q.d.)		1.52 (1.00 to 4.09)	31.49 (-0.10 to 69.65)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		1.46 (0.93 to 3.86)	28.08 (-5.68 to 66.03)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		1.58 (1.05 to 4.22)	34.71 (4.28 to 72.49)
SIM12 PR24-48 RGT	SOF12 + PR12	0.80 (0.51 to 1.54)	-16.50 (-44.03 to 25.13)
B24 PR28-48 RGT		0.31 (0.08 to 0.92)	-54.95 (-82.61 to -4.24)
SOF12 + SIM12 + RBV12		1.08 (0.36 to 1.79)	6.66 (-49.92 to 39.44)
SOF24 + RBV24		0.85 (0.35 to 1.33)	-12.19 (-50.82 to 18.51)
DCV24 + ASU24		1.07 (0.82 to 2.03)	5.87 (-16.41 to 45.77)
SOF12 + LDV12		1.15 (0.95 to 2.15)	12.75 (-4.74 to 50.86)
SOF12 + LDV12 + RBV12		1.15 (0.94 to 2.15)	12.62 (-5.08 to 50.87)
SOF24 + LDV24 + RBV24		1.16 (0.95 to 2.15)	13.15 (-4.19 to 51.00)
GRZ12 + ELB12		1.17 (0.99 to 2.20)	13.89 (-0.89 to 52.44)
DCV12 + ASU12 + BEC12 + RBV12		1.18 (1.00 to 2.22)	14.80 (-0.17 to 53.33)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
DCV12 + ASU12 + BEC12		0.50 (0.00 to 1.61)	-38.56 (-90.76 to 34.71)
GRZ12 + ELB12 (50 mg q.d.)		1.14 (0.93 to 2.12)	11.74 (-6.71 to 49.43)
GRZ18 + ELB18 (50 mg q.d.)		1.11 (0.86 to 2.07)	9.32 (-12.40 to 47.69)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		1.07 (0.78 to 1.98)	6.24 (-19.27 to 44.32)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		1.15 (0.93 to 2.14)	12.37 (-6.51 to 50.75)
B24 PR28-48 RGT	SIM12 PR24-48 RGT	0.38 (0.10 to 1.10)	-39.65 (-68.36 to 4.94)
SOF12 + SIM12 + RBV12		1.34 (0.39 to 2.17)	23.30 (-41.85 to 51.79)
SOF24 + RBV24		1.05 (0.35 to 1.81)	3.29 (-46.10 to 37.21)
DCV24 + ASU24		1.34 (0.95 to 2.16)	22.38 (-3.49 to 49.81)
SOF12 + LDV12		1.45 (1.09 to 2.26)	29.48 (7.75 to 54.07)
SOF12 + LDV12 + RBV12		1.45 (1.08 to 2.26)	29.78 (6.61 to 53.87)
SOF24 + LDV24 + RBV24		1.46 (1.09 to 2.28)	30.29 (7.00 to 54.49)
GRZ12 + ELB12		1.47 (1.13 to 2.30)	31.05 (10.47 to 55.01)
DCV12 + ASU12 + BEC12 + RBV12		1.49 (1.14 to 2.32)	31.88 (11.99 to 55.64)
DCV12 + ASU12 + BEC12		0.60 (0.00 to 1.90)	-25.20 (-76.34 to 44.97)
GRZ12 + ELB12 (50 mg q.d.)		1.44 (1.06 to 2.25)	29.17 (4.99 to 53.44)
GRZ18 + ELB18 (50 mg q.d.)		1.40 (0.99 to 2.18)	26.52 (-1.03 to 50.84)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		1.35 (0.89 to 2.12)	23.15 (-8.46 to 48.76)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		1.45 (1.07 to 2.26)	29.65 (5.47 to 53.97)
SOF12 + SIM12 + RBV12	B24 PR28-48 RGT	3.35 (0.78 to 13.30)	61.35 (-8.48 to 89.63)
SOF24 + RBV24		2.58 (0.71 to 10.84)	40.70 (-13.01 to 77.56)
DCV24 + ASU24		3.53 (1.35 to 13.62)	62.59 (20.94 to 86.38)
SOF12 + LDV12		3.81 (1.50 to 14.37)	70.03 (30.91 to 90.11)
SOF12 + LDV12 + RBV12		3.81 (1.49 to 14.37)	70.05 (29.88 to 90.33)
SOF24 + LDV24 + RBV24		3.84 (1.49 to 14.51)	70.67 (30.61 to 90.82)
GRZ12 + ELB12		3.88 (1.54 to 14.61)	71.52 (33.45 to 90.79)
DCV12 + ASU12 + BEC12 + RBV12		3.92 (1.55 to 14.73)	72.51 (33.89 to 91.55)
DCV12 + ASU12 + BEC12		1.45 (0.01 to 9.95)	11.94 (-48.66 to 85.43)
GRZ12 + ELB12 (50 mg q.d.)		3.79 (1.45 to 14.19)	69.31 (27.66 to 89.45)
GRZ18 + ELB18 (50 mg q.d.)		3.68 (1.40 to 13.98)	66.34 (24.02 to 88.06)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		3.50 (1.33 to 13.44)	62.50 (19.57 to 85.90)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		3.81 (1.47 to 14.50)	69.69 (29.03 to 90.45)
SOF24 + RBV24	SOF12 + SIM12 + RBV12	0.80 (0.29 to 2.38)	-18.29 (-63.84 to 41.94)
DCV24 + ASU24		0.98 (0.76 to 3.43)	-1.59 (-23.25 to 62.66)
SOF12 + LDV12		1.04 (0.89 to 3.72)	4.02 (-10.43 to 69.25)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SOF12 + LDV12 + RBV12		1.05 (0.88 to 3.69)	4.19 (-11.71 to 68.83)
SOF24 + LDV24 + RBV24		1.05 (0.89 to 3.73)	4.42 (-10.69 to 69.43)
GRZ12 + ELB12		1.06 (0.93 to 3.79)	5.45 (-6.98 to 70.57)
DCV12 + ASU12 + BEC12 + RBV12		1.07 (0.95 to 3.83)	5.96 (-5.12 to 72.34)
DCV12 + ASU12 + BEC12		0.48 (0.00 to 2.23)	-40.16 (-97.43 to 47.01)
GRZ12 + ELB12 (50 mg q.d.)		1.04 (0.86 to 3.69)	3.40 (-13.98 to 69.54)
GRZ18 + ELB18 (50 mg q.d.)		1.02 (0.79 to 3.56)	1.68 (-20.37 to 65.93)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.99 (0.71 to 3.44)	-1.29 (-27.41 to 62.52)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		1.04 (0.85 to 3.70)	4.00 (-14.58 to 68.66)
DCV24 + ASU24	SOF24 + RBV24	1.27 (0.90 to 3.73)	19.09 (-9.22 to 65.97)
SOF12 + LDV12		1.39 (1.00 to 3.96)	26.63 (0.08 to 70.84)
SOF12 + LDV12 + RBV12		1.38 (1.00 to 3.97)	26.26 (-0.13 to 71.20)
SOF24 + LDV24 + RBV24		1.39 (1.00 to 4.01)	26.84 (0.19 to 72.23)
GRZ12 + ELB12		1.40 (1.02 to 4.06)	27.77 (2.11 to 72.90)
DCV12 + ASU12 + BEC12 + RBV12		1.42 (1.04 to 4.09)	28.75 (3.65 to 73.71)
DCV12 + ASU12 + BEC12		0.60 (0.00 to 2.67)	-23.99 (-85.75 to 56.69)
GRZ12 + ELB12 (50 mg q.d.)		1.37 (0.99 to 3.92)	25.39 (-1.18 to 70.71)
GRZ18 + ELB18 (50 mg q.d.)		1.33 (0.91 to 3.82)	22.59 (-7.51 to 68.39)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		1.28 (0.84 to 3.64)	19.41 (-13.83 to 64.37)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		1.38 (0.98 to 3.96)	25.95 (-1.48 to 71.36)
SOF12 + LDV12	DCV24 + ASU24	1.07 (0.90 to 1.38)	6.18 (-8.94 to 26.71)
SOF12 + LDV12 + RBV12		1.07 (0.91 to 1.38)	6.60 (-8.87 to 26.59)
SOF24 + LDV24 + RBV24		1.08 (0.91 to 1.38)	7.08 (-8.55 to 26.69)
GRZ12 + ELB12		1.09 (0.96 to 1.39)	7.64 (-4.15 to 27.28)
DCV12 + ASU12 + BEC12 + RBV12		1.09 (0.98 to 1.40)	8.42 (-2.21 to 28.05)
DCV12 + ASU12 + BEC12		0.45 (0.00 to 1.23)	-48.27 (-93.63 to 17.94)
GRZ12 + ELB12 (50 mg q.d.)		1.07 (0.87 to 1.35)	6.05 (-11.67 to 25.03)
GRZ18 + ELB18 (50 mg q.d.)		1.04 (0.80 to 1.32)	3.52 (-17.76 to 23.07)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		1.00 (0.71 to 1.30)	0.31 (-26.07 to 21.47)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		1.07 (0.88 to 1.38)	6.24 (-10.84 to 26.69)
SOF12 + LDV12 + RBV12	SOF12 + LDV12	1.00 (0.88 to 1.13)	0.16 (-11.46 to 10.60)
SOF24 + LDV24 + RBV24		1.01 (0.88 to 1.15)	0.58 (-11.54 to 12.32)
GRZ12 + ELB12		1.01 (0.92 to 1.16)	1.00 (-8.25 to 13.76)
DCV12 + ASU12 + BEC12 + RBV12		1.02 (0.93 to 1.18)	1.77 (-6.40 to 14.87)
DCV12 + ASU12 + BEC12		0.41 (0.00 to 1.08)	-55.80 (-97.63 to 7.10)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
GRZ12 + ELB12 (50 mg q.d.)		1.00 (0.83 to 1.15)	-0.46 (-16.71 to 12.87)
GRZ18 + ELB18 (50 mg q.d.)		0.97 (0.76 to 1.13)	-2.77 (-23.35 to 10.68)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.94 (0.67 to 1.10)	-5.64 (-31.23 to 8.24)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		1.00 (0.83 to 1.15)	0.06 (-16.49 to 12.72)
SOF24 + LDV24 + RBV24	SOF12 + LDV12 + RBV12	1.01 (0.88 to 1.15)	0.46 (-11.74 to 12.85)
GRZ12 + ELB12		1.01 (0.91 to 1.18)	0.82 (-8.41 to 15.25)
DCV12 + ASU12 + BEC12 + RBV12		1.02 (0.93 to 1.19)	1.54 (-6.43 to 15.67)
DCV12 + ASU12 + BEC12		0.41 (0.00 to 1.08)	-55.65 (-97.95 to 7.42)
GRZ12 + ELB12 (50 mg q.d.)		0.99 (0.83 to 1.15)	-0.49 (-16.12 to 12.63)
GRZ18 + ELB18 (50 mg q.d.)		0.97 (0.76 to 1.12)	-2.81 (-23.52 to 10.49)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.94 (0.68 to 1.10)	-5.83 (-31.37 to 8.41)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		1.00 (0.83 to 1.17)	0.05 (-16.51 to 13.84)
GRZ12 + ELB12	SOF24 + LDV24 + RBV24	1.01 (0.91 to 1.17)	0.46 (-8.72 to 14.00)
DCV12 + ASU12 + BEC12 + RBV12		1.01 (0.93 to 1.18)	1.06 (-6.38 to 14.83)
DCV12 + ASU12 + BEC12		0.41 (0.00 to 1.07)	-56.34 (-98.13 to 6.58)
GRZ12 + ELB12 (50 mg q.d.)		0.99 (0.82 to 1.15)	-0.86 (-17.10 to 12.52)
GRZ18 + ELB18 (50 mg q.d.)		0.97 (0.75 to 1.13)	-3.32 (-23.73 to 10.65)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.93 (0.67 to 1.09)	-6.35 (-31.45 to 7.72)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		0.99 (0.83 to 1.15)	-0.52 (-16.09 to 12.34)
DCV12 + ASU12 + BEC12 + RBV12	GRZ12 + ELB12	1.01 (0.93 to 1.11)	0.63 (-6.93 to 9.62)
DCV12 + ASU12 + BEC12		0.40 (0.00 to 1.04)	-57.46 (-98.14 to 4.10)
GRZ12 + ELB12 (50 mg q.d.)		0.99 (0.81 to 1.09)	-1.41 (-18.43 to 7.77)
GRZ18 + ELB18 (50 mg q.d.)		0.96 (0.75 to 1.06)	-4.02 (-24.42 to 5.60)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.93 (0.67 to 1.04)	-7.19 (-32.21 to 3.58)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		0.99 (0.82 to 1.09)	-1.04 (-17.60 to 8.13)
DCV12 + ASU12 + BEC12	DCV12 + ASU12 + BEC12 + RBV12	0.40 (0.00 to 1.03)	-58.40 (-98.67 to 2.92)
GRZ12 + ELB12 (50 mg q.d.)		0.98 (0.81 to 1.06)	-2.13 (-19.13 to 5.89)
GRZ18 + ELB18 (50 mg q.d.)		0.95 (0.74 to 1.05)	-4.86 (-25.43 to 4.64)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.92 (0.66 to 1.03)	-8.05 (-33.44 to 2.90)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		0.98 (0.81 to 1.07)	-1.60 (-18.52 to 6.38)
GRZ12 + ELB12 (50 mg q.d.)	DCV12 + ASU12 + BEC12	2.42 (0.90 to 684.60)	54.73 (-9.54 to 97.61)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
GRZ18 + ELB18 (50 mg q.d.)		2.33 (0.86 to 664.60)	51.32 (-13.34 to 96.12)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		2.24 (0.80 to 646.60)	47.69 (-19.24 to 94.02)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		2.43 (0.91 to 688.40)	55.04 (-8.30 to 97.82)
GRZ18 + ELB18 (50 mg q.d.)	GRZ12 + ELB12 (50 mg q.d.)	0.98 (0.78 to 1.14)	-2.33 (-20.66 to 11.62)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.94 (0.70 to 1.11)	-5.35 (-27.59 to 8.89)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		1.00 (0.85 to 1.19)	0.43 (-13.90 to 15.19)
GRZ12 + ELB12 (50 mg q.d.) + RBV12	GRZ18 + ELB18 (50 mg q.d.)	0.97 (0.74 to 1.17)	-2.96 (-23.98 to 13.38)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		1.03 (0.88 to 1.28)	2.75 (-11.32 to 20.94)
GRZ18 + ELB18 (50 mg q.d.) + RBV18	GRZ12 + ELB12 (50 mg q.d.) + RBV12	1.06 (0.91 to 1.43)	5.82 (-8.19 to 28.08)
Random effect model	Residual deviance	35.41 vs. 39 data points	
	Deviance information criteria	182.546	
Fixed effect model	Residual deviance	35.19 vs. 39 data points	
	Deviance information criteria	181.858	

ASU = asunaprevir; B = boceprevir; BEC = beclabuvir; Crl = credible interval; DAS = dasabuvir; DCV = daclatasvir; ELB = elbasvir; GRZ = grazoprevir; LDV = ledipasvir; OMB = ombitasvir; PAR = paritaprevir; PR = pegylated interferon plus ribavirin; q8 = every 8 hours; q12 = every 12 hours; q.d. = once daily; RBV = ribavirin; RD = risk difference; RGT = response-guided therapy; RIT = ritonavir; RR = relative risk; SIM = simeprevir; SOF = sofosbuvir; T = telaprevir; vs. = versus.

Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.